The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282 ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

Alchemab Therapeutics, whose labs are in Cambridge UK, stands to scoop $415 million from Eli Lilly and Company following a ...

Amyotrophic lateral sclerosis has been a tough area for drug research, but Eli Lilly has been spreading ... deal terms announced Tuesday, Lilly is licensing Alchemab’s ATLX-1282, an antibody ...

In January 2025, Alchemab announced an agreement with Eli Lilly and Company. Under the terms of the agreement, Alchemab will collaborate with Lilly to discover, develop and commercialise up to ...

UK-based Alchemab has secured a licensing agreement worth up to $415m with Eli Lilly for ATLX-1282, its investigational antibody therapy targeting amyotrophic lateral sclerosis (ALS) and other ...